SLC66A1: A Potential Drug Target for Various Diseases (G54896)

Target Name: SLC66A1

NCBI ID: G54896

SLC66A1

SLC66A1: A Potential Drug Target for Various Diseases

SLC66A1 (PQ loop repeat containing 2) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. The protein encoded by this gene is a member of the P-type ATP-binding proteins (PABPs) family, which are known for their role in cellular signaling and metabolism.

SLC66A1 is a 21-kDa protein that is expressed in various tissues and organs, including brain, heart, kidney, and liver. It is localized to the endoplasmic reticulum (ER) and nuclear envelope (NE), and is predominantly expressed in the cytoplasm. SLC66A1 has a unique structure, with a single transmembrane region and a cytoplasmic tail that is involved in its stability and localization to different cellular compartments.

SLC66A1 is involved in a variety of cellular processes, including intracellular signaling, cell survival, and inflammation. It has been shown to play a role in multiple signaling pathways, including the regulation of mitochondrial function, cell adhesion, and neurotransmitter release. SLC66A1 has also been shown to be involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders.

One of the most promising aspects of SLC66A1 is its potential as a drug target. SLC66A1 has been shown to be involved in a variety of cellular processes that are relevant to several diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. Its unique structure and expression patterns make it an attractive target for small molecules, antibodies, or other therapeutic agents that can modulate its function and activity.

In the context of cancer, SLC66A1 has been shown to play a role in multiple signaling pathways that are involved in tumor progression and the development of cancer. For example, SLC66A1 has been shown to be involved in the regulation of mitochondrial function, which is crucial for the growth and survival of cancer cells. Additionally, SLC66A1 has been shown to be involved in the regulation of cell adhesion, which is important for the formation of cancer cells and the development of invasive tumors.

In the context of neurodegenerative diseases, SLC66A1 has been shown to play a role in the regulation of neurotransmitter release and the development of neurodegeneration. For example, SLC66A1 has been shown to be involved in the regulation of dopamine release from brain neurons, which is important for the treatment of Parkinson's disease. Additionally, SLC66A1 has been shown to be involved in the regulation of neurotransmitter release from astrocytes, which is important for the treatment of neurodegenerative diseases such as Alzheimer's disease.

In the context of psychiatric disorders, SLC66A1 has been shown to play a role in the regulation of neurotransmitter release and the development of psychiatric disorders. For example, SLC66A1 has been shown to be involved in the regulation of serotonin release from brain neurons, which is important for the treatment of depression and anxiety disorders. Additionally, SLC66A1 has been shown to be involved in the regulation of neurotransmitter release from microglia, which is important for the treatment of anxiety disorders.

SLC66A1 is a unique protein that has been shown to be involved in multiple cellular processes that are relevant to several diseases. Its structure and expression patterns make it an attractive target for small molecules, antibodies, or other therapeutic agents that can modulate its function and activity. Further research is needed to fully understand the role of SLC66A1 in disease and to develop effective treatments.

Protein Name: Solute Carrier Family 66 Member 1

Functions: Amino acid transporter that specifically mediates the pH-dependent export of the cationic amino acids arginine, histidine and lysine from lysosomes

The "SLC66A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC66A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets